"We know facing a cancer diagnosis can be frightening. But we want you to know that you will be in good hands with us, surrounded by a caring team of compassionate professionals who will be by your side and will hold your hand. We’ll be focused on you and your loved ones as long as you need us."

During the past decade, Compass Oncology Rose Quarter conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 24 clinical trials were completed, i.e. on average, 480% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 8 clinical trials were completed. i.e. 800% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Compass Oncology Rose Quarter" #1 sponsor was "National Cancer Institute (NCI)" with 14 trials, followed by "SWOG Cancer Research Network" with 9 trials sponsored, "GOG Foundation" with 3 trials sponsored, "Alliance for Clinical Trials in Oncology" with 2 trials sponsored and "Genentech, Inc." with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Compass Oncology Rose Quarter" #1 collaborator was "National Cancer Institute (NCI)" with 20 trials as a collaborator, "Cancer and Leukemia Group B" with 6 trials as a collaborator, "NRG Oncology" with 6 trials as a collaborator, "NCIC Clinical Trials Group" with 5 trials as a collaborator and "North Central Cancer Treatment Group" with 4 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Compass Oncology Rose Quarter" are "Fallopian Tube Endometrioid Adenocarcinoma" (5 trials), "Fallopian Tube Mucinous Adenocarcinoma" (5 trials), "Fallopian Tube Transitional Cell Carcinoma" (5 trials), "Ovarian Brenner Tumor" (5 trials) and "Ovarian Endometrioid Adenocarcinoma" (5 trials). Many other conditions were trialed in "Compass Oncology Rose Quarter" in a lesser frequency.

Most popular intervention types in "Compass Oncology Rose Quarter" are "Drug" (28 trials), "Other" (28 trials), "Biological" (15 trials), "Radiation" (8 trials) and "Procedure" (5 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (19 trials), "Paclitaxel" (11 trials), "Quality-of-Life Assessment" (11 trials), "Bevacizumab" (8 trials) and "Carboplatin" (8 trials). Other intervention names were less common.

The vast majority of trials in "Compass Oncology Rose Quarter" are 24 trials for "All" genders and 15 trials for "Female" genders.

Currently, there are NaN active trials in "Compass Oncology Rose Quarter". undefined are not yet recruiting, 2 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Compass Oncology Rose Quarter, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Compass Oncology Rose Quarter, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".